Stem Cell Mobilization by G-CSF by Granulocyte Colony Stimulating Factor Post Myocardial Infarction to Promote Myocyte Repair View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2005-2006

ABSTRACT

Eighty-six patients with heart attacks will be identified at our hospital. Post heart attack we will assess heart function, blood flow to the heart, and heart cell function. We will assess these parameters using nuclear cardiology scans that are used in everyday cardiology practice. The patients will then be divided into 2 groups. One group will receive a medication called G-CSF and the other group will receive a placebo. We will give this drug (1-2ml) for 4 days beneath the skin. We will take the patients blood during this time and measure how the drug affected their blood. The patients will all have the nuclear cardiology tests again in 6 weeks and 6 months to see how their heart is functioning. As well, they will have a six month angiogram. All the patients will otherwise receive optimal care from their Cardiologist. They will be seen at 6, 12, 24, and 52 weeks to assess them clinically. This study will test the effects of G-CSF on the heart function of patients who have had a heart attack. It is a medication that that has been shown in an animal model to improve heart function after a heart attack. It is a medication that has been used for many years to treat patients with cancers and to increase the number of cells donated by healthy bone marrow donors. It has no serious side effects. It works by increasing the number of a person’s own stem cells in the blood. Stem cells are special cells that are present in our bodies that have the ability to form new cells. It had been thought that the heart could not make new cells after it has been damaged. Other investigators have shown that this might not be the case. It is now thought that after an injury, stem cells from the bone marrow can transform into cells of the injured tissue. Therefore, we are trying to increase the number of stem cells in the circulation with G-CSF so as to increase repair in the heart after it has been damaged. This strategy has never been tried in human beings and if successful could greatly reduce death and suffering from heart disease. More... »

URL

https://clinicaltrials.gov/show/NCT00394498

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2995", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Eighty-six patients with heart attacks will be identified at our hospital. Post heart attack we will assess heart function, blood flow to the heart, and heart cell function. We will assess these parameters using nuclear cardiology scans that are used in everyday cardiology practice. The patients will then be divided into 2 groups. One group will receive a medication called G-CSF and the other group will receive a placebo. We will give this drug (1-2ml) for 4 days beneath the skin. We will take the patients blood during this time and measure how the drug affected their blood. The patients will all have the nuclear cardiology tests again in 6 weeks and 6 months to see how their heart is functioning. As well, they will have a six month angiogram. All the patients will otherwise receive optimal care from their Cardiologist. They will be seen at 6, 12, 24, and 52 weeks to assess them clinically. This study will test the effects of G-CSF on the heart function of patients who have had a heart attack. It is a medication that that has been shown in an animal model to improve heart function after a heart attack. It is a medication that has been used for many years to treat patients with cancers and to increase the number of cells donated by healthy bone marrow donors. It has no serious side effects. It works by increasing the number of a person\u2019s own stem cells in the blood. Stem cells are special cells that are present in our bodies that have the ability to form new cells. It had been thought that the heart could not make new cells after it has been damaged. Other investigators have shown that this might not be the case. It is now thought that after an injury, stem cells from the bone marrow can transform into cells of the injured tissue. Therefore, we are trying to increase the number of stem cells in the circulation with G-CSF so as to increase repair in the heart after it has been damaged. This strategy has never been tried in human beings and if successful could greatly reduce death and suffering from heart disease.", 
    "endDate": "2006-10-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00394498", 
    "keywords": [
      "stem cell", 
      "Granulocyte Colony-Stimulating Factor", 
      "myocardial infarction", 
      "Promote", 
      "patient", 
      "heart attack", 
      "hospital", 
      "heart function", 
      "blood flow", 
      "heart", 
      "cell function", 
      "parameter", 
      "cardiology", 
      "medication", 
      "placebo", 
      "drug", 
      "skin", 
      "patient blood", 
      "Weight and Measure", 
      "blood", 
      "angiogram", 
      "optimal care", 
      "cardiologist", 
      "animal model", 
      "Neoplasm", 
      "cell", 
      "bone marrow donor", 
      "serious side effect", 
      "own stem cell", 
      "special cell", 
      "body", 
      "Wound and Injury", 
      "bone marrow", 
      "injured tissue", 
      "circulation", 
      "repair", 
      "human being", 
      "death", 
      "heart disease"
    ], 
    "name": "Stem Cell Mobilization by G-CSF by Granulocyte Colony Stimulating Factor Post Myocardial Infarction to Promote Myocyte Repair", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00394498"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00003.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.248883.d", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.28046.38", 
        "type": "Organization"
      }
    ], 
    "startDate": "2005-09-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s12350-011-9389-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032500143", 
          "https://doi.org/10.1007/s12350-011-9389-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.140133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044432604"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00394498"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00394498'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00394498'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00394498'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00394498'


 

This table displays all metadata directly associated to this object as RDF triples.

70 TRIPLES      16 PREDICATES      58 URIs      48 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00394498 schema:about anzsrc-for:2995
2 anzsrc-for:3048
3 schema:description Eighty-six patients with heart attacks will be identified at our hospital. Post heart attack we will assess heart function, blood flow to the heart, and heart cell function. We will assess these parameters using nuclear cardiology scans that are used in everyday cardiology practice. The patients will then be divided into 2 groups. One group will receive a medication called G-CSF and the other group will receive a placebo. We will give this drug (1-2ml) for 4 days beneath the skin. We will take the patients blood during this time and measure how the drug affected their blood. The patients will all have the nuclear cardiology tests again in 6 weeks and 6 months to see how their heart is functioning. As well, they will have a six month angiogram. All the patients will otherwise receive optimal care from their Cardiologist. They will be seen at 6, 12, 24, and 52 weeks to assess them clinically. This study will test the effects of G-CSF on the heart function of patients who have had a heart attack. It is a medication that that has been shown in an animal model to improve heart function after a heart attack. It is a medication that has been used for many years to treat patients with cancers and to increase the number of cells donated by healthy bone marrow donors. It has no serious side effects. It works by increasing the number of a person’s own stem cells in the blood. Stem cells are special cells that are present in our bodies that have the ability to form new cells. It had been thought that the heart could not make new cells after it has been damaged. Other investigators have shown that this might not be the case. It is now thought that after an injury, stem cells from the bone marrow can transform into cells of the injured tissue. Therefore, we are trying to increase the number of stem cells in the circulation with G-CSF so as to increase repair in the heart after it has been damaged. This strategy has never been tried in human beings and if successful could greatly reduce death and suffering from heart disease.
4 schema:endDate 2006-10-01T00:00:00Z
5 schema:keywords Granulocyte Colony-Stimulating Factor
6 Neoplasm
7 Promote
8 Weight and Measure
9 Wound and Injury
10 angiogram
11 animal model
12 blood
13 blood flow
14 body
15 bone marrow
16 bone marrow donor
17 cardiologist
18 cardiology
19 cell
20 cell function
21 circulation
22 death
23 drug
24 heart
25 heart attack
26 heart disease
27 heart function
28 hospital
29 human being
30 injured tissue
31 medication
32 myocardial infarction
33 optimal care
34 own stem cell
35 parameter
36 patient
37 patient blood
38 placebo
39 repair
40 serious side effect
41 skin
42 special cell
43 stem cell
44 schema:name Stem Cell Mobilization by G-CSF by Granulocyte Colony Stimulating Factor Post Myocardial Infarction to Promote Myocyte Repair
45 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00394498
46 schema:sdDatePublished 2019-03-07T15:22
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher N89977e6b55644ed280b5d819bca88b9f
49 schema:sponsor https://www.grid.ac/institutes/grid.248883.d
50 https://www.grid.ac/institutes/grid.28046.38
51 schema:startDate 2005-09-01T00:00:00Z
52 schema:subjectOf sg:pub.10.1007/s12350-011-9389-5
53 https://doi.org/10.1503/cmaj.140133
54 schema:url https://clinicaltrials.gov/show/NCT00394498
55 sgo:license sg:explorer/license/
56 sgo:sdDataset clinical_trials
57 rdf:type schema:MedicalStudy
58 N89977e6b55644ed280b5d819bca88b9f schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 anzsrc-for:2995 schema:inDefinedTermSet anzsrc-for:
61 rdf:type schema:DefinedTerm
62 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
63 rdf:type schema:DefinedTerm
64 sg:pub.10.1007/s12350-011-9389-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032500143
65 https://doi.org/10.1007/s12350-011-9389-5
66 rdf:type schema:CreativeWork
67 https://doi.org/10.1503/cmaj.140133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044432604
68 rdf:type schema:CreativeWork
69 https://www.grid.ac/institutes/grid.248883.d schema:Organization
70 https://www.grid.ac/institutes/grid.28046.38 schema:Organization
 




Preview window. Press ESC to close (or click here)


...